Votrient approved for advanced kidney cancer

After showing positive clinical data, the FDA has recently approved the drug votrient (pazopanib hydrochloride) for the treatment of advanced kidney cancer.The drug is said to work by restricting proliferation of blood vessels to a developing tumor and as a result starves the tumor of the nutrients or factors it needs to grow.In the USA alone they are approximately 50,000 people who suffer from kidney cancer so its good to see a drug come through the pipeline to market

References
http://health.usnews.com/articles/health/healthday/2009/10/20/votrient-approved-for-advanced-kidney-cancer.html